Security Snapshot

AbbVie Inc. - Common Stock (ABBV) Institutional Ownership

CUSIP: 00287Y109

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

4,087

Shares (Excl. Options)

1,316,003,132

Price

$228.49

Type / Class
Equity / Common Stock
Symbol
ABBV on NYSE
Shares outstanding
1,767,364,935
Price per share
$217.49
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
1,316,003,132
Total reported value
$300,492,651,944
% of total 13F portfolios
0.23%
Share change
+41,112,436
Value change
+$9,372,287,347
Number of holders
4,087
Price from insider filings
$217.49
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • ABBV - AbbVie Inc. - Common Stock is tracked under CUSIP 00287Y109.
  • 4087 institutions reported positions in Q4 2025.
  • Schedule 13D/13G significant owner rows are not currently available.

What Changed

  • Holder count moved from 4,087 to 294 between Q4 2025 and Q1 2026.
  • Reported value moved from $300,492,651,944 to $1,451,457,784.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 00287Y109?
CUSIP 00287Y109 identifies ABBV - AbbVie Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

As of 31 Dec 2025, 4,087 institutional investors reported holding 1,316,003,132 shares of AbbVie Inc. - Common Stock (ABBV). This represents 74% of the company’s total 1,767,364,935 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of AbbVie Inc. - Common Stock (ABBV) together control 48% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 10% 180,779,699 +1.7% 0.6% $41,306,353,424
BlackRock, Inc. 8.6% 151,174,543 +3.6% 0.59% $34,541,871,411
STATE STREET CORP 4.6% 80,940,931 +1.4% 0.62% $18,494,193,324
JPMORGAN CHASE & CO 3% 52,393,323 -7.3% 0.81% $11,971,351,030
GEODE CAPITAL MANAGEMENT, LLC 2.5% 44,629,980 +10% 0.63% $10,179,098,610
MORGAN STANLEY 2.3% 40,041,940 -3.9% 0.55% $9,149,183,466
BANK OF AMERICA CORP /DE/ 1.5% 25,824,399 +2.7% 0.43% $5,900,616,785
NORGES BANK 1.5% 25,668,761 0.63% $5,865,055,201
Capital Research Global Investors 1.4% 25,408,200 +0.7% 1.1% $5,805,529,521
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.4% 25,169,844 -3% 0.89% $5,751,060,095
FMR LLC 1.3% 22,609,389 +7.5% 0.26% $5,166,019,290
NORTHERN TRUST CORP 1.2% 21,733,923 -1.4% 0.63% $4,965,984,066
WELLINGTON MANAGEMENT GROUP LLP 0.84% 14,926,683 +42% 0.6% $3,410,597,797
FRANKLIN RESOURCES INC 0.84% 14,881,504 +2.3% 0.83% $3,400,274,102
Bank of New York Mellon Corp 0.76% 13,499,351 +9.7% 0.54% $3,084,466,589
Capital World Investors 0.74% 13,071,444 +106% 0.41% $2,986,777,322
GOLDMAN SACHS GROUP INC 0.74% 12,995,625 -3% 0.42% $2,969,370,350
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.73% 12,924,311 +2.7% 0.62% $2,953,075,820
Legal & General Group Plc 0.69% 12,133,331 +1.1% 0.61% $2,772,344,798
Capital International Investors 0.66% 11,692,765 +9.2% 0.42% $2,671,982,867
UBS Group AG 0.6% 10,526,920 -10% 0.48% $2,405,295,950
Amundi 0.59% 10,450,406 -0.55% 0.74% $2,387,813,268
DEUTSCHE BANK AG\ 0.57% 10,129,714 +7.1% 0.75% $2,314,538,352
AMERIPRISE FINANCIAL INC 0.57% 10,060,638 +4% 0.52% $2,298,902,337
PRICE T ROWE ASSOCIATES INC /MD/ 0.56% 9,826,388 -7.3% 0.24% $2,245,232,000

Institutional Holders of AbbVie Inc. - Common Stock (ABBV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 6,794,227 $1,451,457,784 +$50,828,433 $217.49 294
2025 Q4 1,316,003,132 $300,492,651,944 +$9,372,287,347 $228.49 4,087
2025 Q3 1,270,015,568 $293,795,490,662 -$3,123,583,240 $231.54 3,878
2025 Q2 1,287,075,518 $238,891,433,790 +$4,866,082,603 $185.62 3,742
2025 Q1 1,261,493,107 $264,023,235,689 -$2,130,141,483 $209.52 3,780
2024 Q4 1,275,092,654 $226,558,537,921 +$1,209,556,751 $177.70 3,709
2024 Q3 1,263,246,128 $249,268,364,641 +$88,413,171 $197.48 3,466
2024 Q2 1,262,725,926 $216,474,972,193 +$1,915,850,329 $171.52 3,339
2024 Q1 1,253,088,393 $227,875,219,935 +$2,788,759,396 $182.10 3,353
2023 Q4 1,239,748,668 $192,192,568,041 +$1,517,401,072 $154.97 3,297
2023 Q3 1,228,903,942 $183,197,476,249 +$1,009,113,820 $149.06 3,092
2023 Q2 1,221,315,614 $164,787,374,519 -$1,664,070,544 $134.73 3,053
2023 Q1 1,233,425,991 $196,519,460,228 +$259,081,467 $159.37 3,117
2022 Q4 1,235,502,434 $199,621,628,438 +$2,752,393,686 $161.61 3,144
2022 Q3 1,221,220,466 $164,097,646,774 +$170,284,213 $134.21 2,949
2022 Q2 1,217,745,031 $186,477,353,594 +$3,489,007,770 $153.16 2,980
2022 Q1 1,203,308,144 $195,040,563,504 +$2,450,810,000 $162.11 3,033
2021 Q4 1,188,323,728 $160,862,723,207 +$1,040,998,406 $135.40 2,954
2021 Q3 1,177,170,536 $127,005,644,713 -$384,320,770 $107.87 2,641
2021 Q2 1,182,050,895 $133,115,260,852 -$647,210,591 $112.64 2,657
2021 Q1 1,186,224,948 $128,344,178,557 -$1,087,268,478 $108.22 2,595
2020 Q4 1,197,885,694 $128,301,295,744 -$1,070,454,735 $107.15 2,580
2020 Q3 1,210,244,308 $105,941,681,033 -$1,507,877,911 $87.59 2,356
2020 Q2 1,226,149,387 $120,286,919,217 +$14,394,795,664 $98.18 2,397
2020 Q1 1,079,313,793 $82,241,542,825 +$791,234,318 $76.19 2,213
2019 Q4 1,067,427,836 $94,486,529,954 +$1,223,798,676 $88.54 2,231
2019 Q3 1,056,424,195 $79,981,092,369 +$2,749,727,052 $75.72 1,995
2019 Q2 1,020,107,599 $74,140,080,434 +$134,418,416 $72.72 2,013
2019 Q1 1,025,594,398 $82,642,729,287 -$1,357,273,013 $80.59 2,023
2018 Q4 1,043,063,858 $96,057,755,521 -$2,268,195,432 $92.19 2,054
2018 Q3 1,064,303,780 $100,606,565,412 -$228,478,920 $94.58 1,952
2018 Q2 1,066,935,394 $98,824,334,101 -$4,621,865,658 $92.65 1,988
2018 Q1 1,115,897,507 $105,577,975,508 -$635,075,420 $94.65 2,010
2017 Q4 1,124,483,239 $108,727,093,427 +$374,684,079 $96.71 1,990
2017 Q3 1,118,458,594 $99,379,513,075 +$1,309,956,795 $88.86 1,792
2017 Q2 1,104,509,124 $80,068,623,904 +$1,082,850,124 $72.51 1,761
2017 Q1 1,097,772,439 $71,530,343,434 +$6,012,078,996 $65.16 1,725
2016 Q4 1,094,423,119 $68,517,301,870 -$1,501,669,878 $62.62 1,686
2016 Q3 1,115,082,886 $70,272,962,866 -$935,916,366 $63.07 1,642
2016 Q2 1,128,170,500 $69,822,885,108 +$1,331,070,628 $61.91 1,624
2016 Q1 1,107,228,663 $63,240,024,329 -$234,331,465 $57.12 1,624
2015 Q4 1,114,783,288 $66,029,826,303 -$1,761,226,133 $59.24 1,627
2015 Q3 1,135,736,480 $61,795,060,747 -$3,097,342,097 $54.41 1,586
2015 Q2 1,197,000,259 $80,428,666,659 +$5,904,487,622 $67.19 1,642
2015 Q1 1,111,667,985 $65,099,745,699 -$591,285,996 $58.54 1,590
2014 Q4 1,121,324,839 $73,375,310,991 -$8,392,175,216 $65.44 1,596
2014 Q3 1,252,517,869 $72,342,438,122 +$8,158,820,153 $57.76 1,493
2014 Q2 1,110,338,015 $62,659,470,218 +$2,575,063,702 $56.44 1,448
2014 Q1 1,066,968,421 $54,829,249,328 +$103,303,847 $51.40 1,413

Sponsored